Source: http://www.google.com/patents/US6004565?dq=5527183
Timestamp: 2016-10-26 04:29:51
Document Index: 773117177

Matched Legal Cases: ['art 14', 'art 14', 'art 11', 'art 12', 'art 11', 'art 12']

Patent US6004565 - Compositions and methods of using compositions with accelerated lymphocyte ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe methods and compositions of the invention and the compounds used in the invention involve a novel immunosuppression mechanism, accelerated lymphocyte homing immunosuppression (ALH-immunosuppression). For example, the compound FTY720 specifically directs lymphocytes to the peripheral lymph nodes,...http://www.google.com/patents/US6004565?utm_source=gb-gplus-sharePatent US6004565 - Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive propertiesAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS6004565 APublication typeGrantApplication numberUS 08/933,738Publication dateDec 21, 1999Filing dateSep 23, 1997Priority dateSep 2, 1997Fee statusPaidAlso published asUS6667025, US20020102279, US20040092603, US20050090558Publication number08933738, 933738, US 6004565 A, US 6004565A, US-A-6004565, US6004565 A, US6004565AInventorsKenji Chiba, Kunitomo AdachiOriginal AssigneeYoshitomi Pharmaceutical Industries, Ltd.Export CitationBiBTeX, EndNote, RefManPatent Citations (6), Non-Patent Citations (121), Referenced by (138), Classifications (16), Legal Events (7) External Links: USPTO, USPTO Assignment, EspacenetCompositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS5037958 *Apr 27, 1987Aug 6, 1991Yoshitomi Pharmaceutical Industries, Ltd.Immunosuppressive factorUS5219884 *Sep 14, 1988Jun 15, 1993Taito Co., Ltd.ImmunosuppressantUS5604229 *Oct 18, 1993Feb 18, 1997Yoshitomi Pharmaceutical Industries, Ltd.2-amino-1,3-propanediol compound and immunosuppressantUS5686479 *Dec 10, 1992Nov 11, 1997Yoshitomi Pharmaceutical Industries, Ltd.Immunosuppressive drugUS5719175 *May 6, 1996Feb 17, 1998Eli Lilly And CompanyProtein kinase C inhibitorsWO1996006068A1 *Aug 22, 1995Feb 29, 1996Yoshitomi Pharmaceutical Industries, Ltd.Benzene compound and medicinal use thereof* Cited by examinerNon-Patent CitationsReference1A. Hamann et al., "Role of α4 -Integrins in Lymphocyte Homing to Mucosal Tissues in Vivo," Journal of Immunology, vol. 152, pp. 3282-3293 (1994).2 *A. Hamann et al., Role of 4 Integrins in Lymphocyte Homing to Mucosal Tissues in Vivo, Journal of Immunology, vol. 152, pp. 3282 3293 (1994).3A. Siegling et al., "A novel multispecific competitor fragment for quantitative PCR analysis of cytokine gene expression in rats," Journal of Immunological Methods, vol. 177, pp. 23-28 (1994).4 *A. Siegling et al., A novel multispecific competitor fragment for quantitative PCR analysis of cytokine gene expression in rats, Journal of Immunological Methods, vol. 177, pp. 23 28 (1994).5B.D. Kahan et al., "Preclinical Evaluation of a New Potent Immunosuppressive Agent, Rapamycin," Transplantation, vol. 52, No. 2, pp. 185-191 (Aug. 1991).6 *B.D. Kahan et al., Preclinical Evaluation of a New Potent Immunosuppressive Agent, Rapamycin, Transplantation, vol. 52, No. 2, pp. 185 191 (Aug. 1991).7B.D. Kahan, "Medical Intelligence, Drug Therapy, Cyclosporine," The New England Journal of Medicine, vol. 321, No. 25, pp. 1725-1738 (Dec. 21, 1989).8 *B.D. Kahan, Medical Intelligence, Drug Therapy, Cyclosporine, The New England Journal of Medicine, vol. 321, No. 25, pp. 1725 1738 (Dec. 21, 1989).9Barry D. Kahan et al., "The Synergistic Interactions In Vitro and In Vivo of Brequinar Sodium with Cyclosporine or Rapamycin aAone and in Triple Combination", Transplantation, vol. 55, No. 4, pp. 894-900 (1993).10 *Barry D. Kahan et al., The Synergistic Interactions In Vitro and In Vivo of Brequinar Sodium with Cyclosporine or Rapamycin aAone and in Triple Combination , Transplantation, vol. 55, No. 4, pp. 894 900 (1993).11C. Berlin et al., "α4β7 Integrin Mediates Lymphocyte Binding to the Mucosal Vascular Addressin MadCAM-1," Cell, vol. 74, pp. 185-195 (Jul. 16, 1993).12 *C. Berlin et al., 4 7 Integrin Mediates Lymphocyte Binding to the Mucosal Vascular Addressin MadCAM 1, Cell, vol. 74, pp. 185 195 (Jul. 16, 1993).13C. Legendre et al., "Prediction of Successful Allograft Rejection Retreatment With OKT3", Transplantation, vol. 53, pp. 94-94 (1992).14C. Legendre et al., "Prediction of Successful Allograft Rejection Retreatment with OKT3," Transplantation, vol. 53, No. 1, pp. 87-90 (Jan. 1992).15 *C. Legendre et al., Prediction of Successful Allograft Rejection Retreatment With OKT3 , Transplantation, vol. 53, pp. 94 94 (1992).16 *C. Legendre et al., Prediction of Successful Allograft Rejection Retreatment with OKT3, Transplantation, vol. 53, No. 1, pp. 87 90 (Jan. 1992).17 *Chiba, K. Adachi, K. Drugs of the Future. 22(1)18 22, Mar. 26, 1997.18Chiba, K. Adachi, K. Drugs of the Future. 22(1)18-22, Mar. 26, 1997.19 *Copending U.S. Application Serial No. 08/801,390, filed Feb. 20, 1997.20D.V. Cramer et al., "The Effect of a New Immunosuppressive Drug, Brequinar Sodium, on Heart, Liver, and Kidney Allograft Rejection in the Rat," Transplantation, vol. 53, No. 2, pp. 303-308 (Feb. 1992).21 *D.V. Cramer et al., The Effect of a New Immunosuppressive Drug, Brequinar Sodium, on Heart, Liver, and Kidney Allograft Rejection in the Rat, Transplantation, vol. 53, No. 2, pp. 303 308 (Feb. 1992).22 *Enosawa, S., et al., Immunopharmacology 34:171 179, 1996.23Enosawa, S., et al., Immunopharmacology 34:171-179, 1996.24European FK506 Multicentre Liver Study Group, "Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection", The Lancet, vol. 344, pp. 423-428 (Aug. 13, 1994).25 *European FK506 Multicentre Liver Study Group, Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection , The Lancet, vol. 344, pp. 423 428 (Aug. 13, 1994).26F. Shanahan, "A Gut Reaction: Lymphoepithelial Communication in the Intestine", Science, vol. 275, pp. 1897-1898 (1997).27 *F. Shanahan, A Gut Reaction: Lymphoepithelial Communication in the Intestine , Science, vol. 275, pp. 1897 1898 (1997).28 *Fujita, T., et al., Bioorgan. Med. Chem. Let. 5(16)1857 1860, 1995.29Fujita, T., et al., Bioorgan. Med. Chem. Let. 5(16)1857-1860, 1995.30G.R. Woollett et al., "Molecular and antigenic heterogeneity of the rat leukocyte-common antigen from thymocytes and T and B lymphocytes," Eur. J. Immunol., vol. 15, pp. 168-173 (1985).31 *G.R. Woollett et al., Molecular and antigenic heterogeneity of the rat leukocyte common antigen from thymocytes and T and B lymphocytes, Eur. J. Immunol., vol. 15, pp. 168 173 (1985).32H. Amemiya et al., "Synergistic Effect of Cylcosporine and Mizoribine on Survival of Dog Renal Allografts," Transplantation, vol. 46, No. 5, pp. 768-771 (Nov. 1988).33 *H. Amemiya et al., Synergistic Effect of Cylcosporine and Mizoribine on Survival of Dog Renal Allografts, Transplantation, vol. 46, No. 5, pp. 768 771 (Nov. 1988).34H.ff.S. Davies et al., "Long-Term Survival of Kidney Allografts in Dogs After Withdrawal of Immunosuppression with Ciclosporin and Azathioprine," Eur. Surg. Res., vol. 21, pp. 65-75 (1989).35 *H.ff.S. Davies et al., Long Term Survival of Kidney Allografts in Dogs After Withdrawal of Immunosuppression with Ciclosporin and Azathioprine, Eur. Surg. Res., vol. 21, pp. 65 75 (1989).36 *Hirose, R, et al., Bioorgan. Med. Chem. Let. 6(22)2647 2650, 1996.37Hirose, R, et al., Bioorgan. Med. Chem. Let. 6(22)2647-2650, 1996.38J. F. Borel, "Pharmacology of Cyclosporine (Sandimmune) IV. Pharmacological Properties in Vivo," Pharmacological Reviews, vol. 41, No. 3, pp. 259-371 (1989).39 *J. F. Borel, Pharmacology of Cyclosporine (Sandimmune) IV. Pharmacological Properties in Vivo, Pharmacological Reviews, vol. 41, No. 3, pp. 259 371 (1989).40J. Fung et al., "A Randomized Trial of Primary Liver Transplantation Under Immunosuppression with FK 506 vs Cyclosporine," Transplantation Proceedings, vol. 23, No. 6, pp. 2977-2983 (Dec. 1991).41 *J. Fung et al., A Randomized Trial of Primary Liver Transplantation Under Immunosuppression with FK 506 vs Cyclosporine, Transplantation Proceedings, vol. 23, No. 6, pp. 2977 2983 (Dec. 1991).42J. Liu et al., "Calcineurin Is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes," Cell, vol. 66, pp. 807-815, (Aug. 23, 1991).43 *J. Liu et al., Calcineurin Is a Common Target of Cyclophilin Cyclosporin A and FKBP FK506 Complexes, Cell, vol. 66, pp. 807 815, (Aug. 23, 1991).44J. Wang et al., "Local Hormone Networks and Intestinal T Cell Homeostasis," Science, vol. 275, pp. 1937-1939 (Mar. 28, 1997).45 *J. Wang et al., Local Hormone Networks and Intestinal T Cell Homeostasis, Science, vol. 275, pp. 1937 1939 (Mar. 28, 1997).46J.C. Howard, "Supply and transport of peptides presented by class I MHC molecules," Curr. Opin. Immunol., vol. 7, pp. 69-76 (1995).47 *J.C. Howard, Supply and transport of peptides presented by class I MHC molecules, Curr. Opin. Immunol., vol. 7, pp. 69 76 (1995).48J.E. Miller et al., "A New Model of Heterotopic Rat Heart Transplantation with Application for In Vivo 31 P Nuclear Magnetic Resonance Spectroscopy," Transplantation, vol. 39, No. 5, pp. 555-558 (May 1985).49 *J.E. Miller et al., A New Model of Heterotopic Rat Heart Transplantation with Application for In Vivo 31 P Nuclear Magnetic Resonance Spectroscopy, Transplantation, vol. 39, No. 5, pp. 555 558 (May 1985).50J.F. Borel et al., "Biological Effects of Cyclosporin A: A New Antilymphocytic Agent," Agents and Actions, vol. 6/4, pp. 468-475 (1976).51 *J.F. Borel et al., Biological Effects of Cyclosporin A: A New Antilymphocytic Agent, Agents and Actions, vol. 6/4, pp. 468 475 (1976).52K. Chiba et al., "FTY720, A Novel Immunosuppressant Possessing Unique Mechanisms. I. Prolongation of Skin Allograft Survival and Synergistic Effect in Combination with Cyclosporine in Rats", Transplant. Proc., vol. 28, No. 2, pp. 1056-1059 (1996).53 *K. Chiba et al., FTY720, A Novel Immunosuppressant Possessing Unique Mechanisms. I. Prolongation of Skin Allograft Survival and Synergistic Effect in Combination with Cyclosporine in Rats , Transplant. Proc., vol. 28, No. 2, pp. 1056 1059 (1996).54Kunitomo Adachi et al., "Design, Synthesis, And Structure-Activity Relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a Novel Immunosuppressant, FTY720", BioMed. Chem. Lett., vol. 5, No. 8, pp. 853-856 (1995).55 *Kunitomo Adachi et al., Design, Synthesis, And Structure Activity Relationships of 2 substituted 2 amino 1,3 propanediols: Discovery of a Novel Immunosuppressant, FTY720 , BioMed. Chem. Lett., vol. 5, No. 8, pp. 853 856 (1995).56L.A. Turka et al., "Guanine Ribonucleotide Depletion Inhibits T Cell Activation," J. Clin. Invest., vol. 87, pp. 940-948 (Mar. 1991).57 *L.A. Turka et al., Guanine Ribonucleotide Depletion Inhibits T Cell Activation, J. Clin. Invest., vol. 87, pp. 940 948 (Mar. 1991).58L.J. Picker et al., "Physiological and Molecular Mechanisms of Lymphocyte Homing," Ann. Rev. Immunol., vol. 10, pp. 561-591 (1992).59 *L.J. Picker et al., Physiological and Molecular Mechanisms of Lymphocyte Homing, Ann. Rev. Immunol., vol. 10, pp. 561 591 (1992).60L.M. McEvoy et al., "Anti-CD43 inhibition of T Cell homing," J. Exp. Med., vol. 185, No. 8, pp. 1493-1498 (Apr. 21, 1997) (Abstract only).61 *L.M. McEvoy et al., Anti CD43 inhibition of T Cell homing, J. Exp. Med., vol. 185, No. 8, pp. 1493 1498 (Apr. 21, 1997) (Abstract only).62M. Slapak et al., "The Use of Low-Dose Cyclosporine in Combination With Azathioprine and Steriods in Renal Transplantation," Transplantation Proceedings, vol. XVII, No. 1, Feb. 1985, pp. 1222-1226.63 *M. Slapak et al., The Use of Low Dose Cyclosporine in Combination With Azathioprine and Steriods in Renal Transplantation, Transplantation Proceedings, vol. XVII, No. 1, Feb. 1985, pp. 1222 1226.64M.J. Dallman et al., "Cytokine Gene Expression: Analysis using Northern Blotting, Polymerase Chain Reaction and in situ Hybridization," Immunological Reviews, No. 119, pp. 163-179 (1991).65M.J. Dallman et al., "Cytokine Gene Transcription in Vascularised Organ Grafts: Analysis Using Semiquantitative Polymerase Chain Reaction," J. Exp. Med., vol. 174, pp. 493-496 (Aug. 1991).66 *M.J. Dallman et al., Cytokine Gene Expression: Analysis using Northern Blotting, Polymerase Chain Reaction and in situ Hybridization, Immunological Reviews, No. 119, pp. 163 179 (1991).67 *M.J. Dallman et al., Cytokine Gene Transcription in Vascularised Organ Grafts: Analysis Using Semiquantitative Polymerase Chain Reaction, J. Exp. Med., vol. 174, pp. 493 496 (Aug. 1991).68 *M.L. Arbon e s et al., Lymphocyte Homing and Leukocyte Rolling and Migration are Impaired in L Selectin Deficient Mice, Immunity, vol. 1, pp. 247 260 (Jul. 1994).69M.L. Arbones et al., "Lymphocyte Homing and Leukocyte Rolling and Migration are Impaired in L-Selectin-Deficient Mice," Immunity, vol. 1, pp. 247-260 (Jul. 1994).70M.R. Jackson et al., "Assembly and Intracellular Transport of MHC Class I Molecules," Annu. Rev. Cell Biol., vol. 9, pp. 207-235 (1993).71 *M.R. Jackson et al., Assembly and Intracellular Transport of MHC Class I Molecules, Annu. Rev. Cell Biol., vol. 9, pp. 207 235 (1993).72N. Inamura et al., "Prolongation of Skin Allograft Survival in Rats by a Novel Immunosuppressive Agent, FK506," Transplantation, vol. 45, No. 1, pp. 206-209 (Jan. 1988).73 *N. Inamura et al., Prolongation of Skin Allograft Survival in Rats by a Novel Immunosuppressive Agent, FK506, Transplantation, vol. 45, No. 1, pp. 206 209 (Jan. 1988).74P. Cresswell, "Assembly, Transport, and Function of MHC Class II Molecules," Annu. Rev. Immunol., vol. 12, pp. 259-293 (1994).75 *P. Cresswell, Assembly, Transport, and Function of MHC Class II Molecules, Annu. Rev. Immunol., vol. 12, pp. 259 293 (1994).76R. Schwartz et al., "Drug-induced Immunological Tolerance," Nature, vol. 183, p. 1682 (Jun. 13, 1959).77 *R. Schwartz et al., Drug induced Immunological Tolerance, Nature, vol. 183, p. 1682 (Jun. 13, 1959).78S. Sasaki et al., "Fungal Metabolites. Part 14. Novel Potent Immunosuppressants, Mycestericins, Produced by Mycelia sterilia," The Journal of Antibiotics, vol. 47, No. 4, pp. 420-433 (Apr. 1994).79 *S. Sasaki et al., Fungal Metabolites. Part 14. Novel Potent Immunosuppressants, Mycestericins, Produced by Mycelia sterilia, The Journal of Antibiotics, vol. 47, No. 4, pp. 420 433 (Apr. 1994).80S. Suzuki et al., "Long-Term Graft Acceptance in Allografted Rats and Dogs by Treatment With a Novel Immunosuppressant, FTY720", Transplant. Proc., vol. 28, No. 3, pp. 1375-1376 (1996).81 *S. Suzuki et al., Long Term Graft Acceptance in Allografted Rats and Dogs by Treatment With a Novel Immunosuppressant, FTY720 , Transplant. Proc., vol. 28, No. 3, pp. 1375 1376 (1996).82Seiichi Suzuki et al., "A Novel Immunosuppressant, FTY720, With A Unique Mechanism of Action, Induces Long-Term Graft Acceptance in Rat and Dog Allotransplantation", Transplantation, vol. 61, No. 2, pp. 200-205 (1996).83 *Seiichi Suzuki et al., A Novel Immunosuppressant, FTY720, With A Unique Mechanism of Action, Induces Long Term Graft Acceptance in Rat and Dog Allotransplantation , Transplantation, vol. 61, No. 2, pp. 200 205 (1996).84 *Suzuki, S. et al., Transplant. Proc. 28(4)2049 2050, Apr. 1996.85Suzuki, S. et al., Transplant. Proc. 28(4)2049-2050, Apr. 1996.86 *Suzuki, S., et al., Immunology. 89:518 523, 1996.87Suzuki, S., et al., Immunology. 89:518-523, 1996.88T. B. Issekutz, "Inhibition of In Vivo Lymphocyte Migration to Inflammation and Homing to Lymphoid Tissues by the TA-2 Monoclonal Antibody," The Journal of Immunology, vol. 147, No. 12, pp. 4178-4184 (Dec. 15, 1991).89 *T. B. Issekutz, Inhibition of In Vivo Lymphocyte Migration to Inflammation and Homing to Lymphoid Tissues by the TA 2 Monoclonal Antibody, The Journal of Immunology, vol. 147, No. 12, pp. 4178 4184 (Dec. 15, 1991).90T. Fujita et al., "Fungal Metabolites, Part 11. A Potent Immunosuppressive Activity Found in Isaria sinclairii Metabolite," The Journal of Antibiotics, vol. 47, No. 2, pp. 208-215 (Feb. 1994).91T. Fujita et al., "Fungal Metabolites, Part 12. Potent Immunosuppressant, 14-Deoxomyriocin, (2S, 3R, 4R)--(E) -2-Amino-3,4-Dihydroxy-2-Hydroxymethyleicos-6-Enoic Acid and Structure-Activity Relationships of Myriocin Derivatives," The Journal of Antibiotics, vol. 47, No. 2, pp. 216-224 (Feb. 1994).92T. Fujita et al., "Potent Immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols", J. Med. Chem., vol. 39, pp. 4451-4459 (1996).93 *T. Fujita et al., Fungal Metabolites, Part 11. A Potent Immunosuppressive Activity Found in Isaria sinclairii Metabolite, The Journal of Antibiotics, vol. 47, No. 2, pp. 208 215 (Feb. 1994).94 *T. Fujita et al., Fungal Metabolites, Part 12. Potent Immunosuppressant, 14 Deoxomyriocin, (2S, 3R, 4R) (E) 2 Amino 3,4 Dihydroxy 2 Hydroxymethyleicos 6 Enoic Acid and Structure Activity Relationships of Myriocin Derivatives, The Journal of Antibiotics, vol. 47, No. 2, pp. 216 224 (Feb. 1994).95 *T. Fujita et al., Potent Immunosuppressants, 2 alkyl 2 aminopropane 1,3 diols , J. Med. Chem., vol. 39, pp. 4451 4459 (1996).96T. Kawaguchi et al., "FTY720, A Novel Immunosuppressant Possessing Unique Mechanisms. III. Synergistic Prolongation of Canine Renal Allograft Survival in Combination With Cyclosporine A", Transplant. Proc., vol. 28, No. 2, pp. 1062-1063 (1996).97 *T. Kawaguchi et al., FTY720, A Novel Immunosuppressant Possessing Unique Mechanisms. III. Synergistic Prolongation of Canine Renal Allograft Survival in Combination With Cyclosporine A , Transplant. Proc., vol. 28, No. 2, pp. 1062 1063 (1996).98T. Kino et al., "FK-506, A Novel Immunosuppressant Isolated from a Streptomyces, I. Fermentation, Isolation and Physico-Chemical and Biological Characteristics," The Journal of Antibiotics, vol. 40, No. 9, pp. 1249-1255 (1987).99T. Kino et al., "FK-506, A Novel Immunosuppressant Isolated from a Streptomyces, II. Immunosuppressive Effect of FK-506 In Vitro," The Journal of Antibiotics, vol. 40, No. 9, pp. 1256-1265 (Sep. 1987).100 *T. Kino et al., FK 506, A Novel Immunosuppressant Isolated from a Streptomyces, I. Fermentation, Isolation and Physico Chemical and Biological Characteristics, The Journal of Antibiotics, vol. 40, No. 9, pp. 1249 1255 (1987).101 *T. Kino et al., FK 506, A Novel Immunosuppressant Isolated from a Streptomyces, II. Immunosuppressive Effect of FK 506 In Vitro, The Journal of Antibiotics, vol. 40, No. 9, pp. 1256 1265 (Sep. 1987).102T. Tamatani et al., "Characterization of the rat leukocyte integrin, CD11/CD18, by the use of LFA-1 subunit-specific monoclonal antibodies," Eur. J. Immunol., vol. 21, pp. 627-633 (1991).103 *T. Tamatani et al., Characterization of rat LECAM 1 (L selectin) by the use of monoclonal antibodies and evidence for the presence of soluble LECAM 1 in rat sera, Eur. J. Immunol., vol. 23, pp. 2181 2188, (1993).104T. Tamatani et al., Characterization of rat LECAM-1 (L-selectin) by the use of monoclonal antibodies and evidence for the presence of soluble LECAM-1 in rat sera, Eur. J. Immunol., vol. 23, pp. 2181-2188, (1993).105 *T. Tamatani et al., Characterization of the rat leukocyte integrin, CD11/CD18, by the use of LFA 1 subunit specific monoclonal antibodies, Eur. J. Immunol., vol. 21, pp. 627 633 (1991).106T. Tanaka et al., "Characterization of a CD3-like Rat T Cell Surface Antigen Recognized by a Monoclonal Antibody," The Journal of Immunology, vol. 142, No. 8, pp. 2791-2795 (Apr. 15, 1989).107 *T. Tanaka et al., Characterization of a CD3 like Rat T Cell Surface Antigen Recognized by a Monoclonal Antibody, The Journal of Immunology, vol. 142, No. 8, pp. 2791 2795 (Apr. 15, 1989).108Tetsuro Fujita et al., "Simple Compounds, 2-alkyl-2-amino-1,3-propanediols Have Potent Immunosuppressive Activity", BioMed. Chem. Lett., vol. 5, No. 8, pp. 847-852 (1995).109 *Tetsuro Fujita et al., Simple Compounds, 2 alkyl 2 amino 1,3 propanediols Have Potent Immunosuppressive Activity , BioMed. Chem. Lett., vol. 5, No. 8, pp. 847 852 (1995).110W.A. Lee et al., "Bioavailability Improvement of Mycophenolic Acid Through Amino Ester Derivatization," Pharmaceutical Research, vol. 7, No. 2, pp. 161-166 (1990).111 *W.A. Lee et al., Bioavailability Improvement of Mycophenolic Acid Through Amino Ester Derivatization, Pharmaceutical Research, vol. 7, No. 2, pp. 161 166 (1990).112Y. Hoshino et al., "FTY720, A Novel Immunosuppressant Possessing Unique Mechanisms. II. Long-Term Graft Survival Induction in Rat Heterotopic Cardiac Allografts and Synergistic Effect in Combination with Cyclosporine A", Transplant. Proc., vol. 28, No. 2, pp. 1060-1061 (1996).113 *Y. Hoshino et al., FTY720, A Novel Immunosuppressant Possessing Unique Mechanisms. II. Long Term Graft Survival Induction in Rat Heterotopic Cardiac Allografts and Synergistic Effect in Combination with Cyclosporine A , Transplant. Proc., vol. 28, No. 2, pp. 1060 1061 (1996).114Y. Imai et al., "Sulphation requirement for GlyCAM-1, an endothelial ligand for L-selectin," Nature, vol. 361, pp. 555-557 (Feb. 11, 1993).115 *Y. Imai et al., Sulphation requirement for GlyCAM 1, an endothelial ligand for L selectin, Nature, vol. 361, pp. 555 557 (Feb. 11, 1993).116Y. Kokado et al., "Low-dose ciclosporin mizoribine and prednisolone in renal transplantation: A New triple-drug therapy," Clin. Transplantation, vol. 4, pp. 191-197 (1990).117 *Y. Kokado et al., Low dose ciclosporin mizoribine and prednisolone in renal transplantation: A New triple drug therapy, Clin. Transplantation, vol. 4, pp. 191 197 (1990).118Y. Masaki et al., "Microchimerism and Heart Allograft Acceptance," Transplantation Proceedings, vol. 27, No. 1, pp. 148-150 (Feb. 1995).119 *Y. Masaki et al., Microchimerism and Heart Allograft Acceptance, Transplantation Proceedings, vol. 27, No. 1, pp. 148 150 (Feb. 1995).120Y. Masubuchi et al., "FTY720, A Novel Immunosuppressant, Possessing Unique Mechanisms. IV. Prevention of Graft Versus Host Reactions in Rats", Transplant. Proc., vol. 28, No. 2, pp. 1064-1065 (1996).121 *Y. Masubuchi et al., FTY720, A Novel Immunosuppressant, Possessing Unique Mechanisms. IV. Prevention of Graft Versus Host Reactions in Rats , Transplant. Proc., vol. 28, No. 2, pp. 1064 1065 (1996).* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS6197829 *Jun 12, 2000Mar 6, 2001Welfide CorporationExternal preparation of 2-amino-2-(2-(4-octylphenyl)ethyl) propane-1,3-diol or pharmaceutically acceptable salts thereof for topical administrationUS6437165Aug 30, 2001Aug 20, 2002Merck & Co., Inc.Phosphate derivatives as immunoregulatory agentsUS6489335 *Feb 18, 2000Dec 3, 2002Gholam A. PeymanTreatment of ocular diseaseUS6667025 *Jun 15, 1999Dec 23, 2003Mitsubishi Pharma CorporationCompositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive propertiesUS6872383Jan 30, 2003Mar 29, 2005Sucampo AgUse of macrolide compounds for the treatment of dry eyeUS7063857Apr 26, 2000Jun 20, 2006Sucampo AgUse of macrolide compounds for the treatment of dry eyeUS7083802Jul 31, 2003Aug 1, 2006Advanced Ocular Systems LimitedTreatment of ocular diseaseUS7083803Jan 6, 2004Aug 1, 2006Advanced Ocular Systems LimitedOcular solutionsUS7087237Sep 19, 2003Aug 8, 2006Advanced Ocular Systems LimitedOcular solutionsUS7186880 *Dec 16, 2002Mar 6, 2007Japan Science And Technology CorporationAdult T cell leukemia model animalUS7189748Oct 12, 2005Mar 13, 2007Forbes Medi-Tech (Research), Inc.Compounds and methods for treating insulin resistance and cardiomyopathyUS7199150Jul 12, 2004Apr 3, 2007Sankyo Company, LimitedAmino alcohol compoundsUS7241812Aug 12, 2005Jul 10, 2007Praecis Pharmaceuticals, Inc.Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activityUS7354574Nov 7, 2002Apr 8, 2008Advanced Ocular Systems LimitedTreatment of ocular diseaseUS7638551Jan 9, 2007Dec 29, 2009Sankyo Company, LimitedAmino alcohol compounds or phosphonic acid derivatives thereofUS7691563May 20, 2004Apr 6, 2010Sanofi-Aventis Pharma GmbhMethod for alleviating pain using sphingosine-1-phosphate and related compounds, and assays for identifying such compoundsUS7732476Jan 31, 2006Jun 8, 2010University Of South FloridaLeukemia treatment method and compositionUS7781617Jul 15, 2005Aug 24, 2010Kyorin Pharmaceutical Co., LtdEffective use method of medicaments and method of preventing expression of side effectUS7795472Oct 7, 2005Sep 14, 2010Kyorin Pharmaceutical Co., Ltd.Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride and hydrates thereof, and intermediates in the production thereofUS7807854Dec 31, 2009Oct 5, 2010Kyorin Pharmaceutical Co., Ltd.Effective use method of medicaments and method of preventing expression of side effectUS7811822Jul 19, 2007Oct 12, 2010Neuronova AbModulation of neural stem cells and neural progenitor cellsUS7833966Nov 21, 2006Nov 16, 2010Peyman Gholam AEnhanced ocular neuroprotection and neurostimulationUS7838562Jun 18, 2004Nov 23, 2010University Of ConnecticutMethods of inhibiting vascular permeability and apoptosisUS7910617Feb 23, 2005Mar 22, 2011Sankyo Company, LimitedMethod for suppressing the number of peripheral blood lymphocytes using an amino alcohol compoundUS7910626Mar 22, 2011Novartis AgUse of S1P receptor agonists in heart diseasesUS8048928Oct 5, 2006Nov 1, 2011Kyorin Pharmaceutical Co., Ltd.Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver diseaseUS8067396Jul 24, 2009Nov 29, 2011Sankyo Company, LimitedAmino alcohol compounds or phosphonic acid derivatives thereofUS8101650Jan 24, 2012Daiichi Sankyo Company, LimitedMethod for treating a immunology-related diseaseUS8202840Jun 19, 2012Minu L.L.C.Enhanced ocular neuroprotection and neurostimulationUS8217028Jun 18, 2009Jul 10, 2012Glaxo Group Limited1,2,4-oxadiazole indole compoundsUS8232319Aug 7, 2007Jul 31, 2012Kyorin Pharmaceutical Co., Ltd.Amino phosphate derivative and S1P receptor modulator having same as an active ingredientUS8242101Apr 22, 2010Aug 14, 2012University Of South FloridaLeukemia treatment method and compositionUS8258150Aug 17, 2007Sep 4, 2012The University Of ChicagoTreatment of inflammatory diseasesUS8273748Aug 7, 2007Sep 25, 2012Kyorin Pharmaceutical Co., Ltd.Amino alcohol derivative and immunosuppresive agent having same as an active ingredientUS8309768Nov 29, 2011Nov 13, 2012The Ohio State University Research FoundationFTY720-derived anticancer agentsUS8318704Aug 31, 2010Nov 27, 2012Neuronova AbModulation of neural stem cells and neural progenitor cellsUS8318811Feb 5, 2007Nov 27, 2012Kyorin Pharmaceutical Co., Ltd.Method for treating an inflammatory bowel disease using 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediol or a salt thereofUS8318812Jun 1, 2007Nov 27, 2012The Ohio State University Research FoundationTherapeutic agents for the treatment of lymphoid malignanciesUS8329730Apr 29, 2009Dec 11, 2012Glaxo Group LimitedCompoundsUS8362071Apr 16, 2010Jan 29, 2013The Ohio State University Research FoundationAntiadhesion agentsUS8461362Jun 11, 2013The Ohio State University Research FoundationProtein phosphatase 2A-activating agentsUS8476305Feb 6, 2009Jul 2, 2013Kyorin Pharmaceutical Co., Ltd.Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredientUS8519006Sep 17, 2010Aug 27, 2013Novartis AgUse of sphingosine-1 phosphate (S1P) receptor agonists for the treatment of brain degenerative diseasesUS8653026Dec 20, 2012Feb 18, 2014Diapin Therapeutics LlcTreatment of type 2 diabetes with FTY720US9101575Sep 30, 2010Aug 11, 2015The University Of ConnecticutMethods of inhibiting vascular permeability and apoptosisUS9101576Aug 6, 2012Aug 11, 2015The University Of ChicagoTreatment of inflammatory diseasesUS9271992Jan 29, 2010Mar 1, 2016Fraunhofer-Geselleschaft Zur Forderung Der Angewandten Forschung E.VMethod for alleviating pain using sphingosine-1-phosphate and related compounds, and assays for identifying such compoundsUS9370497Aug 5, 2015Jun 21, 2016The University Of ChicagoTreatment of inflammatory diseasesUS9415024Jun 13, 2013Aug 16, 2016Novartis AgAminoalkanol derivativesUS20020155511 *Sep 7, 2001Oct 24, 2002Carolyn HorrocksNovel antibody compositions for the negative selection of specific rat leukocyte subsetsUS20030003099 *Jun 7, 2002Jan 2, 2003Philip LakeImmunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejectionUS20030106079 *Dec 16, 2002Jun 5, 2003Takashi OhashiAdult T cell leukemia model animalUS20040058894 *Jan 9, 2003Mar 25, 2004Doherty George A.Selective S1P1/Edg1 receptor agonistsUS20040087662 *Feb 21, 2002May 6, 2004Marc BigaudUse of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft functionUS20040092435 *Nov 7, 2002May 13, 2004Peyman Gholam A.Treatment of ocular diseaseUS20040198763 *Jan 16, 2004Oct 7, 2004Sucampo AgMethod of treating dry eye with a macrolide compoundUS20040214897 *Jul 22, 2002Oct 28, 2004Carole WelschUses for 2-amino-2-propane-1,3-diolsUS20050025810 *Jul 31, 2003Feb 3, 2005Gholam PeymanTreatment of ocular diseaseUS20050032744 *May 20, 2004Feb 10, 2005Aventis Pharma Deutschland GmbhMethod for alleviating pain using sphingosine-1-phosphate and related compounds, and assays for identifying such compoundsUS20050043386 *Jul 12, 2004Feb 24, 2005Sankyo Company, LimitedAmino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing theseUS20050063996 *Sep 19, 2003Mar 24, 2005Gholam PeymanOcular solutionsUS20050063997 *Jan 6, 2004Mar 24, 2005Gholam PeymanOcular solutionsUS20050070506 *Jan 14, 2003Mar 31, 2005Doherty George A.Selective s1p1/edg1 receptor agonistsUS20050090520 *Sep 10, 2004Apr 28, 2005Per LindquistTreatment of disease or injury of the nervous system with FTY720US20050181018 *Apr 14, 2005Aug 18, 2005Peyman Gholam A.Ocular drug deliveryUS20050215531 *May 15, 2003Sep 29, 2005Thomas BaumrukerUse of edg receptor binding agents in cancerUS20050222092 *Jul 23, 2003Oct 6, 2005Volker BrinkmannUse of s1p receptor agonists in heart diseasesUS20060079542 *Oct 12, 2005Apr 13, 2006Therapei Pharmaceuticals, Inc.Compounds and methods for treating insulin resistance and cardiomyopathyUS20060135786 *Aug 12, 2005Jun 22, 2006Praecis Phamaceuticals, Inc.Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activityUS20060153842 *Mar 9, 2006Jul 13, 2006Philip LakeImmunosuppressive combination and its use in the treatment or prophylaxis or insulin-producing cell graft rejectionUS20060223866 *Feb 6, 2006Oct 5, 2006Praecis Pharmaceuticals, Inc.Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activityUS20060228394 *Jun 12, 2006Oct 12, 2006Gholam PeymanOcular solutionsUS20070014760 *Jul 18, 2005Jan 18, 2007Peyman Gholam AEnhanced recovery following ocular surgeryUS20070015697 *Nov 1, 2005Jan 18, 2007Peyman Gholam AEnhanced ocular neuroprotection and neurostimulationUS20070072839 *Jan 31, 2006Mar 29, 2007University Of South FloridaLeukemia Treatment Method and CompositionUS20070105933 *Dec 11, 2006May 10, 2007Sankyo Company, LimitedAmino alcohol compoundsUS20070270499 *Jan 18, 2007Nov 22, 2007Carole WelschUse for 2-amino-2-propane-1, 3-diolsUS20080015261 *Sep 26, 2007Jan 17, 2008Marc BigaudUse of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft functionUS20080039530 *Jun 18, 2004Feb 14, 2008University Of ConnecticutMethods of Inhibiting Vascular Permeability and ApoptosisUS20080064662 *May 22, 2007Mar 13, 2008Praecis Pharmaceuticals IncorporatedMethods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activityUS20080139662 *Dec 17, 2004Jun 12, 2008Volker BrinkmannUse of Sphingosine-1-Phosphate (S1P) Receptor Agonists For the Treatment of Brain Degenerative DiseasesUS20080161410 *Oct 14, 2004Jul 3, 2008Ernst KustersAminoalkanol DerivativesUS20080199465 *Apr 22, 2008Aug 21, 2008Philip LakeImmunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejectionUS20080207941 *Oct 7, 2005Aug 28, 2008Kyorin Pharmaceutical Co., Ltd.Process for Producing 2-Amino-2-[2-[4-(3-Benzyloxyphenylthio)-2-Chlorophenyl]Ethyl]-1,3-Propanediol Hydrochloride and Hydrates Thereof, and Intermediates in the Production ThereofUS20080213276 *Jul 19, 2007Sep 4, 2008Per LindquistModulation of neural stem cells and neural progenitor cellsUS20090042772 *Oct 13, 2008Feb 12, 2009Transition Therapeutics Inc.Compounds and methods of treating insulin resistance and cardiomyopathyUS20090137685 *Feb 5, 2007May 28, 2009Kyorin Pharmaceutical Co., Ltd.Therapeutic Agent for Inflammatory Bowel Disease Containing as Active Ingredient 2-Amino-1,3-Propanediol Derivative, or Method for Treating Inflammatory Bowel DiseaseUS20090209495 *Apr 9, 2009Aug 20, 2009Thomas BaumrukerUse of edg receptor binding agents in cancerUS20090253802 *Oct 5, 2006Oct 8, 2009Takashi KanekoTherapeutic Agent for Treating liver Disease Containing 2-Amino-1,3-Propanediol Derivative as Active Ingredient, and Method for Treating Liver DiseaseUS20090325907 *Aug 7, 2007Dec 31, 2009Yasushi KohnoAmino phosphate derivative and s1p receptor modulator having same as an active ingredientUS20100010000 *Aug 7, 2007Jan 14, 2010Yasushi KohnoAmino alcohol derivative and immunosuppresive agent having same as an active ingredientUS20100010053 *Jun 18, 2009Jan 14, 2010Jose Luis Castro PineiroCompoundsUS20100022655 *Jun 1, 2007Jan 28, 2010The Ohio State University Research FoundationTherapeutic Agents For The Treatment Of Lymphoid MalignanciesUS20100029729 *Feb 4, 2010Jose Luis Castro PineiroCompoundsUS20100035842 *Feb 11, 2010Sankyo Company, LimitedAmino alcohol compounds or phosphonic acid derivatives thereofUS20100099606 *Dec 31, 2009Apr 22, 2010Shinji KudouEffective use method of medicaments and method of preventing expression of side effectUS20100137257 *Jan 29, 2010Jun 3, 2010Sanofi-Aventis Deutschland GmbhMethod for alleviating pain using sphingosine-1-phosphate and related compounds, and assays for identifying such compoundsUS20100152235 *Feb 24, 2010Jun 17, 2010Jag Paul HeerOxadiazole derivatives active on sphingosine-1-phosphate (s1p)US20100227849 *Sep 9, 2010University Of South FloridaLeukemia treatment method and compositionUS20100267673 *Oct 21, 2010The Ohio Sate University Research FoundationProtein phosphatase 2a-activating agentsUS20100267820 *Apr 16, 2010Oct 21, 2010The Ohio State University Research FoundationAntiadhesion agentsUS20100310547 *Aug 17, 2007Dec 9, 2010Soliven Betty CTreatment of Inflammatory DiseasesUS20110039889 *Apr 29, 2009Feb 17, 2011Colin David EldredCompoundsUS20110086839 *Jun 18, 2009Apr 14, 2011Jose Luis Castro PineiroCompoundsUS20110124739 *Sep 17, 2010May 26, 2011Volker BrinkmannUse of Sphingosine-1-phosphate (S1P) Receptor Agonists for the Treatment of Brain Degenerative DiseasesUS20110136739 *Jun 9, 2011Volker BrinkmannUse of S1P Receptor Agonists in Heart DiseasesUS20110189184 *Aug 31, 2010Aug 4, 2011Neuronova AbModulation of neural stem cells and neural progenitor cellsUS20110236382 *Sep 29, 2011Philip LakeImmunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejectionCN1838961B *May 15, 2004Apr 22, 2015G�盖斯林格Use of s1pCN1893934BDec 17, 2004May 26, 2010诺瓦提斯公司Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseasesCN100479814CFeb 21, 2002Apr 22, 2009诺瓦提斯公司Use of accelerated lymphocyte homing agents for manufacture of medicament for treating delayed graft function in tissue transplantCN101791406BDec 17, 2004Aug 14, 2013诺瓦提斯公司Use of sphingosine-1-phosphate (S1P) receptor agonists for the treatment of brain degenerative diseasesCN101905023BJul 15, 2005Jul 11, 2012杏林制药株式会社Method of effectively using medicine and method concerning prevention of side effectDE202004021680U1Apr 6, 2004Apr 22, 2010Mitsubishi Pharma Corp.Feste pharmazeutische ZusammensetzungEP1481680A1 *May 30, 2003Dec 1, 2004Aventis Pharma Deutschland GmbHUse of S1PEP1772145A1 *Jul 15, 2005Apr 11, 2007Kyorin Pharmaceutical Co., Ltd.Method of effectively using medicine and method concerning prevention of side effectEP1944026A2May 15, 2003Jul 16, 2008Novartis AGUse of EDG receptor binding agents in cancerEP1955696A2May 15, 2003Aug 13, 2008Novartis AGUse of EDG receptor binding agents in cancerEP2008650A2Apr 6, 2004Dec 31, 2008Novartis AGSolid oral composition comprising a S 1 P receptor agonist and a sugar alcoholEP2046315A2 *Jun 1, 2007Apr 15, 2009The Ohio State University Research FoundationTherapeutic agents for the treatment of lymphoid malignanciesEP2213285A2 *Dec 17, 2004Aug 4, 2010Novartis AGUse of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseasesEP2316431A1Apr 6, 2004May 4, 2011Novartis AGSolid oral composition comprising a S1P receptor agonist and a sugar alcoholEP2769713A1Apr 6, 2004Aug 27, 2014Novartis AGSolid oral composition comprising a S1P receptor agonist and a sugar alcoholWO2002067915A1 *Feb 21, 2002Sep 6, 2002Novartis AgUse of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft functionWO2002100148A2 *Jun 7, 2002Dec 19, 2002Novartis AgTreatment or prophylaxis of insulin-producing cell graft rejectionWO2002100148A3 *Jun 7, 2002Apr 22, 2004Novartis AgTreatment or prophylaxis of insulin-producing cell graft rejectionWO2003009836A2 *Jul 22, 2002Feb 6, 2003Novartis AgNew uses for 2-amino-2-propane-1,3-diolsWO2003009836A3 *Jul 22, 2002Nov 27, 2003Novartis AgNew uses for 2-amino-2-propane-1,3-diolsWO2004010987A2 *Jul 23, 2003Feb 5, 2004Novartis AgUse of s1p receptor agonists in heart diseasesWO2004010987A3 *Jul 23, 2003Apr 15, 2004Volker BrinkmannUse of s1p receptor agonists in heart diseasesWO2004105773A2 *May 15, 2004Dec 9, 2004Sanofi-Aventis Deutschland GmbhUse of s1pWO2004105773A3 *May 15, 2004Apr 27, 2006Sanofi Aventis DeutschlandUse of s1pWO2005058295A2 *Dec 17, 2004Jun 30, 2005Novartis AgUse of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseasesWO2005058295A3 *Dec 17, 2004Nov 24, 2005Novartis AgUse of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseasesWO2012135561A1Mar 30, 2012Oct 4, 2012Novartis AgFormulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diolWO2014011083A2Jul 5, 2013Jan 16, 2014Alla Chem, LlcPharmaceutical composition having improved flowability, medicinal agent, and method for producing and using sameWO2015015254A1Dec 10, 2013Feb 5, 2015Aizant Drug Research Solutions Pvt LtdPharmaceutical compositions of fingolimodWO2016042493A1Sep 16, 2015Mar 24, 2016Aizant Drug Research Pvt. LtdPharmaceutical compositions of fingolimod* Cited by examinerClassifications U.S. Classification424/278.1, 560/163, 560/29, 514/653, 514/487, 564/355, 514/546, 564/223International ClassificationA61K31/135, A61K31/13, A61P37/06, A61K45/00, G01N33/49Cooperative ClassificationY10S514/885, A61K31/135European ClassificationA61K31/135Legal EventsDateCodeEventDescriptionSep 23, 1997ASAssignmentOwner name: YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD., JAPANFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHIBA, KENJI;ADACHI, KUNITOMO;REEL/FRAME:008738/0205Effective date: 19970908Dec 12, 2000ASAssignmentOwner name: WELFIDE CORPORATION, JAPANFree format text: CHANGE OF NAME;ASSIGNOR:YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.;REEL/FRAME:011356/0717Effective date: 20000401Apr 24, 2001CCCertificate of correctionMar 18, 2002ASAssignmentOwner name: MITSUBISHI PHARMA CORPORATION, JAPANFree format text: MERGER;ASSIGNOR:WELFIDE CORPORATION;REEL/FRAME:012698/0582Effective date: 20011001May 20, 2003FPAYFee paymentYear of fee payment: 4May 25, 2007FPAYFee paymentYear of fee payment: 8May 25, 2011FPAYFee paymentYear of fee payment: 12RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services